Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...

Twenty-four weeks of bepirovirsen achieves a functional cure in approximately one-fifth of patients with chronic hepatitis B.

The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or compensated cirrhosis.

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all treatment. Reading time 3 minutes An experimental medication called ...

Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...

Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...

Please provide your email address to receive an email when new articles are posted on . Hepcludex injection was approved for chronic hepatitis D without cirrhosis or with compensated cirrhosis. It is ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new study by the University of Virginia and Virginia Commonwealth ...

T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged ...